Anti-vWF nanobody (TTP)
Caplacizumab
Brand names: Cablivi
Adult dose
Dose: 10mg IV before plasma exchange day 1, then 10mg SC OD until 30 days post-PEX (or per protocol)
Route: IV / Subcutaneous
Frequency: OD
Clinical pearls
- NICE TA667: acquired thrombotic thrombocytopenic purpura (aTTP) alongside plasma exchange and immunosuppression
- BSH TTP guideline: triple therapy (PEX + steroid + caplacizumab; rituximab considered)
- Specialist haematology
Contraindications
- Active major bleeding
- Severe coagulopathy
- Hypersensitivity
Side effects
- Bleeding (epistaxis, gingival, GI)
- Headache
- Fatigue
- Pyrexia
- Hypersensitivity
Interactions
- Anticoagulants/antiplatelets/heparin (additive bleeding)
Monitoring
- Platelet count
- ADAMTS13 activity
- Bleeding
Reference: BNF; NICE TA667; BSH TTP guideline; SmPC; https://bnf.nice.org.uk/drugs/caplacizumab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO